Literature DB >> 2290114

Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.

J Isola1, O P Kallioniemi, J M Korte, T Wahlström, R Aine, M Helle, H Helin.   

Abstract

Steroid hormone receptors and reactivity for Ki-67 proliferation antigen were studied immunohistochemically in non-neoplastic post-menopausal human ovary and in 29 ovarian cancers. In the normal ovary, oestrogen (OR) and progesterone receptors (PR) were found in the surface epithelium and PR also in the ovarian stroma. Of the ovarian carcinomas 38 per cent (11/29) contained OR and 69 per cent (20/29) PR. Oestrogen receptor expression was confined to malignant cells, whereas PR was present occasionally also in the tumour stroma. In most cases, ORs and PRs were found only in a small population of cancer cells. The growth fractions assessed by the percentage of Ki-67-positive cells ranged from 1 to 59 per cent (mean 19.7 per cent) with a significant correlation (r = 0.74, P less than 0.0001) to S-phase values (mean 12.9 per cent, range 1.2-25.9 per cent) determined by DNA flow cytometry. High Ki-67 (greater than or equal to 15 per cent) and S-phase levels (greater than or equal to 7.5 per cent) correlated with advanced disease stage and patient survival but not with OR or PR status, suggesting that hormone-receptor pathways and proliferative activity are not related in ovarian cancer. Positive OR status, however, identified patients with a better prognosis (P = 0.02), suggesting a correlation with tumour differentiation. The independent prognostic value of oestrogen receptor status and Ki-67 remains to be determined, but the prognostic impact of Ki-67 was comparable to that of S-phase values.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2290114     DOI: 10.1002/path.1711620404

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

Review 1.  Local role of progesterone in the ovary during the periovulatory interval.

Authors:  Charles L Chaffin; Richard L Stouffer
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

2.  Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer.

Authors:  Ramtin Rahmanzadeh; Prakash Rai; Jonathan P Celli; Imran Rizvi; Bettina Baron-Lühr; Johannes Gerdes; Tayyaba Hasan
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

3.  p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.

Authors:  P Röhlke; K Milde-Langosch; C Weyland; U Pichlmeier; W Jonat; T Löning
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Ki-67 is an indicator of progression of neuroendocrine tumors.

Authors:  Noriko Kimura; Wakako Miura; Takao Noshiro; Yukio Miura; Tsuneo Ookuma; Hiroshi Nagura
Journal:  Endocr Pathol       Date:  1994-12       Impact factor: 3.943

5.  The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.

Authors:  Guro Aune; Astrid K Stunes; Solveig Tingulstad; Oyvind Salvesen; Unni Syversen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2011-06-11

6.  MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival.

Authors:  Brian C Grieb; Xi Chen; Christine M Eischen
Journal:  Mol Cancer Res       Date:  2014-05-27       Impact factor: 5.852

7.  Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma?

Authors:  G Valente; R Orecchia; S Gandolfo; M Arnaudo; R Ragona; S Kerim; G Palestro
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

8.  Estrogen stimulation of ovarian surface epithelial cell proliferation.

Authors:  W Bai; B Oliveros-Saunders; Q Wang; M E Acevedo-Duncan; S V Nicosia
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

9.  Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features.

Authors:  P C Huettner; D S Weinberg; J M Lage
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

10.  Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors.

Authors:  P Roger; P Pujol; A Lucas; P Baldet; H Rochefort
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.